JP2005511619A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511619A5
JP2005511619A5 JP2003543612A JP2003543612A JP2005511619A5 JP 2005511619 A5 JP2005511619 A5 JP 2005511619A5 JP 2003543612 A JP2003543612 A JP 2003543612A JP 2003543612 A JP2003543612 A JP 2003543612A JP 2005511619 A5 JP2005511619 A5 JP 2005511619A5
Authority
JP
Japan
Prior art keywords
prevention
treatment
active ingredient
heart disease
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003543612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511619A (ja
Filing date
Publication date
Priority claimed from DE10156249A external-priority patent/DE10156249A1/de
Application filed filed Critical
Publication of JP2005511619A publication Critical patent/JP2005511619A/ja
Publication of JP2005511619A5 publication Critical patent/JP2005511619A5/ja
Withdrawn legal-status Critical Current

Links

JP2003543612A 2001-11-15 2002-11-11 ｃＧＭＰ−特異的ホスホジエステラーゼ９Ａの調節 Withdrawn JP2005511619A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10156249A DE10156249A1 (de) 2001-11-15 2001-11-15 Regulation der cGMP-spezifischen Phosphodiesterase 9A
PCT/EP2002/012550 WO2003041725A2 (de) 2001-11-15 2002-11-11 REGULATION DER cGMP-SPEZIFISCHEN PHOSPHODIESTERASE 9A

Publications (2)

Publication Number Publication Date
JP2005511619A JP2005511619A (ja) 2005-04-28
JP2005511619A5 true JP2005511619A5 (enExample) 2006-01-05

Family

ID=7705937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543612A Withdrawn JP2005511619A (ja) 2001-11-15 2002-11-11 ｃＧＭＰ−特異的ホスホジエステラーゼ９Ａの調節

Country Status (6)

Country Link
US (1) US20040266736A1 (enExample)
EP (1) EP1448210A2 (enExample)
JP (1) JP2005511619A (enExample)
AU (1) AU2002337186A1 (enExample)
DE (1) DE10156249A1 (enExample)
WO (1) WO2003041725A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
EP1829964A4 (en) * 2004-12-08 2009-03-04 Takeshi Yamamoto METHOD OF STUDYING A SEQUENCE OF A GENE
DE102005024494A1 (de) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
MX344770B (es) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * Derivados de 6-cicloalquil-1,5-dihidro-pirazolo (3,4-d) pirimidin-4-onas y su uso como inhibidores de pde9a.
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CA3132895C (en) 2019-03-08 2024-05-14 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4211239C2 (de) * 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase

Similar Documents

Publication Publication Date Title
JP2005511619A5 (enExample)
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ME02688B (me) Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
IL160253A0 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
MX2009003921A (es) Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
JP2006514116A5 (enExample)
JP2005509503A5 (enExample)
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
JP2005505605A5 (enExample)
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
CA2457982A1 (en) Use of nefiracetam for treating neurodegeneration
PT1534296E (pt) UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA
DE60322871D1 (de) Thaltende zubereitungen
NO20041878D0 (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
JP2004530642A5 (enExample)
WO2005025545A3 (en) Pharmaceutical formulation for controlled release of selodenoson
JP2004059440A5 (enExample)
TH48054A3 (th) วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม
RU2002103738A (ru) Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2000122597A (ru) Лекарственное средство Витал-I для лечения острых респираторных заболеваний
SE9902674D0 (sv) New composition